Article

Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure - Results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study

University of North Carolina at Chapel Hill, North Carolina, United States
Circulation (Impact Factor: 14.95). 05/2005; 111(19):2454-60. DOI: 10.1161/01.CIR.0000165065.82609.3D
Source: PubMed

ABSTRACT The prognostic value of serum sodium in patients hospitalized for worsening heart failure has not been well defined.
The Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study randomized 949 patients with systolic dysfunction hospitalized for worsening heart failure to receive 48 to 72 hours of intravenous milrinone or placebo in addition to standard therapy. In a retrospective analysis, we investigated the relationship between admission serum sodium and the primary end point of days hospitalized for cardiovascular causes within 60 days of randomization, as well as the secondary end points of in-hospital mortality, 60-day mortality, and 60-day mortality/rehospitalization. The number of days hospitalized for cardiovascular causes was higher in the lowest sodium quartile: 8.0 (4.5, 18.5) versus 6 (4, 13) versus 6 (4, 11.5) versus 6 (4, 12) days (P<0.015 for comparison with the lowest quartile). Lower serum sodium was associated with higher in-hospital and 60-day mortality: 5.9% versus 1% versus 2.3% versus 2.3% (P<0.015) and 15.9% versus 6.4% versus 7.8% versus 7% (P=0.002), respectively. There was a trend toward higher mortality/rehospitalization for patients who were in the lowest sodium quartile. Multivariable-adjusted Cox proportional hazards analysis showed that serum sodium on admission, when modeled linearly, predicted increased 60-day mortality: sodium (per 3-mEq/L decrease) had a hazard ratio of 1.18 with a 95% CI of 1.03 to 1.36 (P=0.018).
In patients hospitalized for worsening heart failure, admission serum sodium is an independent predictor of increased number of days hospitalized for cardiovascular causes and increased mortality within 60 days of discharge.

Download full-text

Full-text

Available from: Gary Michael Felker, Dec 12, 2013
0 Followers
 · 
213 Views
  • Source
    • "CHF severity can be measured with the symptomatic classification scale of the New York Heart Association (NYHA) [1]. Classification via NYHA scale has been proved to be a risk factor for mortality [2], [3]. Heart rate variability (HRV) is the variation over time of the period between consecutive heartbeats (RR intervals) [4] and is usually extracted from electrocardiographic signal (ECG) recorded through a noninvasive technique. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This study aims to develop an automatic classifier for risk assessment in patients suffering from congestive heart failure (CHF). The proposed classifier separates lower risk patients from higher risk ones, using standard long-term heart rate variability (HRV) measures. Patients are labeled as lower or higher risk according to the New York Heart Association classification (NYHA). A retrospective analysis on two public Holter databases was performed, analyzing the data of 12 patients suffering from mild CHF (NYHA I and II), labeled as lower risk, and 32 suffering from severe CHF (NYHA III and IV), labeled as higher risk. Only patients with a fraction of total heartbeats intervals (RR) classified as normal-to-normal (NN) intervals (NN/RR) higher than 80% were selected as eligible in order to have a satisfactory signal quality. Classification and regression tree (CART) was employed to develop the classifiers. A total of 30 higher risk and 11 lower risk patients were included in the analysis. The proposed classification trees achieved a sensitivity and a specificity rate of 93.3% and 63.6%, respectively, in identifying higher risk patients. Finally, the rules obtained by CART are comprehensible and consistent with the consensus showed by previous studies that depressed HRV is a useful tool for risk assessment in patients suffering from CHF.
    05/2013; 17(3):727-33. DOI:10.1109/JBHI.2013.2244902
  • Source
    • "In the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure Study, a low serum sodium concentration upon admission to the hospital was an independent predictor of prolonged hospitalization for cardiovascular causes and of a high mortality within 60 days after discharge from the hospital [33]. In contrast to hypercholesterolemia as a predictor of death in patients suffering from coronary artery disease, a low serum total cholesterol has been associated with a marked increase in mortality in patients presenting with advanced HF. Rauchhaus et al. reported that, in patients with CHF, the chance of survival increased by 25% for each mmol/l increment in total cholesterol, independently of the etiology of HF, age, LVEF, and exercise capacity [34]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In industrialized countries, chronic heart failure (HF) is a major illness and cause of death. However, because of the paucity of specific clinical manifestations of HF, its early diagnosis and management might be challenging. Therefore, biochemical markers of HF are now being closely scrutinized. An ideal biochemical marker should be a prognostic indicator, should assist in the early diagnosis, reflect the therapeutic response, and help grading the risk associated with each stage of HF. This review summarizes our current understanding of biochemical markers of HF.
    Journal of Cardiology 12/2011; 59(1):1-7. DOI:10.1016/j.jjcc.2011.11.001 · 2.57 Impact Factor
  • Source
    • "In the Acute and Chronic Therapeutic Impact of Vasopressin Antagonist in Chronic Heart Failure Trial (ACTIV in CHF), hyponatraemia was observed in 22% of patients at the time of admission for AHF, and predicted mortality at 60 days after discharge [12]. In the Outcomes of Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure Study (OPTIME- CHF), patients in the lowest plasma sodium quartile had longer hospital stay and higher mortality compared to other plasma sodium quartiles [1]. Hyponatraemia on admission has been identified as one of the most important overall prognostic markers in acute heart failure risk prediction models published by Lee et al. [4] and by Felker et al. [7]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Previous studies suggest that hyponatraemia is a marker of neurohormonal activation and increased mortality in patients with acute heart failure (AHF). Although diabetes is a common co-morbidity in heart failure, no prior study has considered the impact of serum glucose on this relationship. Over four consecutive months we prospectively registered all patients admitted due to AHF. Sodium and glucose levels were determined immediately upon admission. Patients were followed through admission and for the next 6 months. Of 342 patients enrolled, complete data were available for 331 patients. Hyponatraemia (sodium <135 mmol/L) was detected in 22% of patients. However, 47% of patients with hyponatraemia had concomitant hyperglycaemia (glucose level >11 mmol/L). Hyponatraemia was associated with increased 6-month mortality (21 vs. 8%, p=0.002). This association was restricted to patients who had hyponatraemia without concomitant hyperglycaemia. The 6-month mortality of patients with and without hyponatraemia was 11% versus 10% (p=0.87) when hyperglycaemia was present versus 29% and 7% (p<0.001) when hyperglycaemia was absent. In this preliminary study, hyperglycaemia-associated hyponatraemia was present in a significant proportion of patients admitted with AHF. In patients with hyperglycaemia, hyponatraemia had no prognostic significance, whereas in patients without hyperglycaemia, hyponatraemia remained a powerful predictor of mortality. These results need confirmation in a larger study.
    European Journal of Heart Failure 03/2008; 10(2):196-200. DOI:10.1016/j.ejheart.2008.01.008 · 6.58 Impact Factor
Show more